Peptide-based therapy in lupus: Promising data

Advances in Experimental Medicine and Biology

Volumn 601, Issue , 2007, Pages 105-112

  Monneaux, Fanny ^a   Muller, Sylviane ^a  

^a INSTITUT DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; EPITOPE; IMMUNOSUPPRESSIVE AGENT; PEPTIDE;

ANIMAL; AUTOIMMUNE DISEASE; CHEMISTRY; HUMAN; IMMUNE SYSTEM; IMMUNOLOGY; INFLAMMATION; METABOLISM; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

ADRENAL CORTEX HORMONES; ANIMALS; AUTOANTIGENS; AUTOIMMUNE DISEASES; CYCLOPHOSPHAMIDE; EPITOPES; HUMANS; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; PEPTIDES; T-LYMPHOCYTES;

EID: 34848820385     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-72005-0_11     Document Type: Conference Paper

References (41)

1. Allen, S.D., Rawale, S.V., Whitacre, C.C. and Kaumaya, P.T. (2005) Therapeutic peptidomimetic strategies for autoimmune diseases: Costimulation blockade. J. Pept. Res. 65, 591-604.
2. Amital, H., Heilweil, M., Ulmansky, R., Szafer, F., Bar-Tana, R., Morel, L., Foster, M.H., Mostoslavsky, G., Eilat, D., Pizov, G. and Naparstek, Y. (2005) Treatment with a lamininderived peptide suppresses lupus nephritis. J. Immunol. 175, 5516-5523.
3. Anderton, S.M. (2001) Peptide-based immunotherapy of autoimmunity: A path of puzzles, paradoxes and possibilities. Immunology 104, 367-376.
4. Benkirane, N., Guichard, G., Briand, J.P. and Muller, S. (1996) Exploration of requirements for peptidomimetic immune recognition. Antigenic and immunogenic properties of reduced peptide bond pseudopeptide analogues of a histone hexapeptide. J. Biol. Chem. 271, 33218-33224.
5. Ben-Yedidia, T., Beignon, A.S., Partidos, C.D., Muller, S. and Arnon, R. (2002) A retroinverso peptide analogue of influenza virus hemagglutinin B-cell epitope 91-108 induces a strong mucosal and systemic immune response and confers protection in mice after intranasal immunization. Mol. Immunol. 39, 323-331.
6. Briand, J.P., Guichard, G., Dumortier, H. and Muller, S. (1995) Retro-inverso peptidomimetics as new immunological probes. Validation and application to the detection of antibodies in rheumatic diseases. J. Biol. Chem. 270, 20686-20691.
7. Decker, P., Le Moal, A., Briand, J.P. and Muller, S. (2000) Identification of a minimal T cell epitope recognized by antinucleosome Th cells in the C-terminal region of histone H4. J. Immunol. 165, 654-662.
8. Fairchild, P.J. (1997) Altered peptide ligands: Prospects for immune intervention in autoimmune disease. Eur. J. Immunogenet. 24, 155-167.
9. Guichard, G., Benkirane, N., Zeder-Lutz, G., van Regenmortel, M.H., Briand, J.P. and Muller, S. (1994) Antigenic mimicry of natural L-peptides with retro-inverso-peptidomimetics. Proc. Natl. Acad. Sci. U.S.A. 91, 9765-9769.
10. Hahn, B.H., Singh, R.P., La Cava, A. and Ebling, F.M. (2005) Tolerogenic treatment of lupus mice with consensus peptide induces Foxp3-expressing, apoptosis-resistant, TGFbetasecreting CD8+ T cell suppressors. J. Immunol. 175, 7728-7737.
11. Hahn, B.H., Singh, R.R., Wong, W.K., Tsao, B.P., Bulpitt, K. and Ebling, F.M. (2001) Treatment with a consensus peptide based on amino acid sequences in autoantibodies prevents T cell activation by autoantigens and delays disease onset in murine lupus. Arthritis Rheum. 44, 432-441.
12. Isenberg, D. and Rahman, A. (2006) Systemic lupus erythematosus-2005 annus mirabilis? Nat. Clin. Pract. Rheumatol. 2, 145-152.
13. Jameson, B.A., McDonnell, J.M., Marini, J.C. and Korngold, R. (1994) A rationally designed CD4 analogue inhibits experimental allergic encephalomyelitis. Nature 368, 744-746.
14. Kaliyaperumal, A., Michaels, M.A. and Datta, S.K. (1999) Antigen-specific therapy of murine lupus nephritis using nucleosomal peptides: Tolerance spreading impairs pathogenic function of autoimmune T and B cells. J. Immunol. 162, 5775-5783.
15. Kang, H.K., Michaels, M.A., Berner, B.R. and Datta, S.K. (2005) Very low-dose tolerance with nucleosomal peptides controls lupus and induces potent regulatory T cell subsets. J. Immunol. 174, 3247-3255.
16. Kaul, A., D'Cruz, D. and Hughes, G.R.V. (2006) New therapies for systemic lupus erythematosus: Has the future arrived? Future Rheumatol. 1, 235-247.
17. Kotzin, B.L. (1996) Systemic lupus erythematosus. Cell 85, 303-306.
18. Larché, M. and Wraith, D.C. (2005) Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat. Med. 11, S69-S76.
19. Liu, E.H., Siegel, R.M., Harlan, D.M. and O'Shea, J.J. (2007) T cell-directed therapies: Lessons learned and future prospects. Nat. Immunol. 8, 25-30.
20. Marino, M., Ruvo, M., De Falco, S. and Fassina, G. (2000) Prevention of systemic lupus erythematosus in MRL/lpr mice by administration of an immunoglobulin-binding peptide. Nat. Biotechnol. 18, 735-739.
21. Mattioli, M. and Reichlin, M. (1973) Physical association of two nuclear antigens and mutual occurrence of their antibodies: The relationship of the SM and RNAprotein (MO) systems in SLE sera. J. Immunol. 110, 1318-1324.
22. Mézière, C., Viguier, M., Dumortier, H., Lo-Man, R., Leclerc, C., Guillet, J.G., Briand, J.P. and Muller, S. (1997) In vivo T helper cell response to retro-inverso peptidomimetics. J. Immunol. 159, 3230-3237.
23. Monneaux, F., Briand, J.P. and Muller, S. (2000) B and T cell immune response to small nuclear ribonucleoprotein particles in lupus mice: Autoreactive CD4(+) T cells recognize a T cell epitope located within the RNP80 motif of the 70K protein. Eur. J. Immunol. 30, 2191-2200.
24. Monneaux, F., Dumortier, H., Steiner, G., Briand, J.P. and Muller, S. (2001) Murine models of systemic lupus erythematosus: B and T cell responses to spliceosomal ribonucleoproteins in MRL/Fas(lpr) and (NZB x NZW)F(1) lupus mice. Int. Immunol. 13, 1155-1163.
25. Monneaux, F., Hoebeke, J., Sordet, C., Nonn, C., Briand, J.P., Maillère, B., Sibillia, J. and Muller, S. (2005) Selective modulation of CD4+ T cells from lupus patients by a promiscuous, protective peptide analog. J. Immunol. 175, 5839-5847.
26. Monneaux, F., Lozano, J.M., Patarroyo, M.E., Briand, J.P. and Muller, S. (2003) T cell recognition and therapeutic effect of a phosphorylated synthetic peptide of the 70K snRNP protein administered in MR/lpr mice. Eur. J. Immunol. 33, 287-296.
27. Monneaux, F. and Muller, S. (2001) Key sequences involved in the spreading of the systemic autoimmune response to spliceosomal proteins. Scand. J. Immunol. 54, 45-54.
28. Monneaux, F. and Muller, S. (2002) Epitope spreading in systemic lupus erythematosus: Identification of triggering peptide sequences. Arthritis Rheum. 46, 1430-1438.
29. Monneaux, F. and Muller, S. (2004) Peptide-based immunotherapy of systemic lupus erythematosus. Autoimmun. Rev. 3, 16-24.
30. Monneaux, F., Parietti, V., Briand, J.P. and Muller, S. (2004) Intramolecular T cell spreading in unprimed MRL/lpr mice: Importance of the U1-70k protein sequence 131-151. Arthritis Rheum. 50, 3232-3238.
31. Pinilla, C., Appel, J.R., Campbell, G.D., Buencamino, J., Benkirane, N., Muller, S. and Greenspan, N.S. (1998) All-D peptides recognized by an anti-carbohydrate antibody identified from a positional scanning library. J. Mol. Biol. 283, 1013-1025.
32. Pinnas, J.L., Northway, J.D. and Tan, E.M. (1973) Antinucleolar antibodies in human sera. J. Immunol. 111, 996-1004.
33. Root-Bernstein, R. (2006) Peptides vaccines against arthritis. Future Rheumatol. 1, 339-344.
34. Sela, M. and Mozes, E. (2004) Therapeutic vaccines in autoimmunity. Proc. Natl. Acad. Sci. U.S.A. 101 Suppl 2, 14586-14592.
35. Singh, R.R. (2000) The potential use of peptides and vaccination to treat systemic lupus erythematosus. Curr. Opin. Rheumatol. 12, 399-406.
36. Stemmer, C., Quesnel, A., Prévost-Blondel, A., Zimmermann, C., Muller, S., Briand, J.P. and Pircher, H. (1999) Protection against lymphocytic choriomeningitis virus infection induced by a reduced peptide bond analogue of the H-2Db-restricted CD8(+) T cell epitope GP33. J. Biol. Chem. 274, 5550-5556.
37. Suen, J.L., Chuang, Y.H., Tsai, B.Y., Yau, P.M. and Chiang, B.L. (2004) Treatment of murine lupus using nucleosomal T cell epitopes identified by bone marrow-derived dendritic cells. Arthritis Rheum. 50, 3250-3259.
38. Toskos, G.C. (1999) Overview of cellular function in systemic lupus erytheatosus. In: Lahita R. (Ed), Systemic Lupus Erythematosus, 3rd ed., Academic Press, San Dego, pp. 17-54.
39. Wu, H.Y. and Staines, N.A. (2004) A deficiency of CD4+CD25+ T cells permits the development of spontaneous lupus-like disease in mice, and can be reversed by induction of mucosal tolerance to histone peptide autoantigen. Lupus 13, 192-200.
40. Wu, H.Y., Ward, F.J. and Staines, N.A. (2002) Histone peptide-induced nasal tolerance: Suppression of murine lupus. J. Immunol. 169, 1126-1134.
41. Zinger, H., Eilat, E., Meshorer, A. and Mozes, E. (2003) Peptides based on the complementaritydetermining regions of a pathogenic autoantibody mitigate lupus manifestations of (NZB x NZW)F1 mice via active suppression. Int. Immunol. 15, 205-214.